mGlu5 negative allosteric modulators

a patent review (2013 - 2016)

Research output: Contribution to journalReview articleResearchpeer-review

11 Citations (Scopus)

Abstract

Introduction: The pursuit of small molecule mGlu5 NAMs as treatments for a variety of psychiatric and neurodegenerative disorders has developed into a mature field. In addition to extensive preclinical studies, multiple compounds have advanced into clinical trials with the most advanced studies occurring in patients with FXS, PD-LID, and MDD. Areas covered: This review begins with an update of the clinical activity with mGlu5 NAMs, and then moves into a summary of patent applications filed since 2013. The summaries are organized into three separate sections: (1) inventions centered on improvements to existing clinical compounds; (2) new small molecules that maintain the prototypical disubstituted alkyne chemotype found in many mGlu5 NAM compounds; and (3) new small molecules that are not from a disubstituted alkyne chemotype. Expert opinion: It is a critical moment for mGlu5 NAM research as recent reports from clinical trials have included some significant disappointments that have blunted prior optimism. Still, research in this area remains active, and recent years have added several more attractive small molecules to this field. There is now an arsenal of diverse chemotypes available to continue to probe this target in the hopes that a drug may yet emerge.

Original languageEnglish
Pages (from-to)691-706
Number of pages16
JournalExpert Opinion on Therapeutic Patents
Volume27
Issue number6
DOIs
StatePublished - 3 Jun 2017

Fingerprint

Alkynes
Clinical Trials
Expert Testimony
Research
Neurodegenerative Diseases
Psychiatry
Pharmaceutical Preparations
Therapeutics
Optimism

Keywords

  • Basimglurant
  • Parkinson’s disease
  • anxiety
  • depression
  • dipraglurant
  • fragile X syndrome
  • levodopa-induced dyskinesia
  • mavoglurant
  • metabotropic glutamate receptor subtype 5
  • negative allosteric modulator

Cite this

@article{ab2d41506a8049e1b5398e152896e527,
title = "mGlu5 negative allosteric modulators: a patent review (2013 - 2016)",
abstract = "Introduction: The pursuit of small molecule mGlu5 NAMs as treatments for a variety of psychiatric and neurodegenerative disorders has developed into a mature field. In addition to extensive preclinical studies, multiple compounds have advanced into clinical trials with the most advanced studies occurring in patients with FXS, PD-LID, and MDD. Areas covered: This review begins with an update of the clinical activity with mGlu5 NAMs, and then moves into a summary of patent applications filed since 2013. The summaries are organized into three separate sections: (1) inventions centered on improvements to existing clinical compounds; (2) new small molecules that maintain the prototypical disubstituted alkyne chemotype found in many mGlu5 NAM compounds; and (3) new small molecules that are not from a disubstituted alkyne chemotype. Expert opinion: It is a critical moment for mGlu5 NAM research as recent reports from clinical trials have included some significant disappointments that have blunted prior optimism. Still, research in this area remains active, and recent years have added several more attractive small molecules to this field. There is now an arsenal of diverse chemotypes available to continue to probe this target in the hopes that a drug may yet emerge.",
keywords = "Basimglurant, Parkinson’s disease, anxiety, depression, dipraglurant, fragile X syndrome, levodopa-induced dyskinesia, mavoglurant, metabotropic glutamate receptor subtype 5, negative allosteric modulator",
author = "Emmitte, {Kyle Allen}",
year = "2017",
month = "6",
day = "3",
doi = "10.1080/13543776.2017.1280466",
language = "English",
volume = "27",
pages = "691--706",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

mGlu5 negative allosteric modulators : a patent review (2013 - 2016). / Emmitte, Kyle Allen.

In: Expert Opinion on Therapeutic Patents, Vol. 27, No. 6, 03.06.2017, p. 691-706.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - mGlu5 negative allosteric modulators

T2 - a patent review (2013 - 2016)

AU - Emmitte, Kyle Allen

PY - 2017/6/3

Y1 - 2017/6/3

N2 - Introduction: The pursuit of small molecule mGlu5 NAMs as treatments for a variety of psychiatric and neurodegenerative disorders has developed into a mature field. In addition to extensive preclinical studies, multiple compounds have advanced into clinical trials with the most advanced studies occurring in patients with FXS, PD-LID, and MDD. Areas covered: This review begins with an update of the clinical activity with mGlu5 NAMs, and then moves into a summary of patent applications filed since 2013. The summaries are organized into three separate sections: (1) inventions centered on improvements to existing clinical compounds; (2) new small molecules that maintain the prototypical disubstituted alkyne chemotype found in many mGlu5 NAM compounds; and (3) new small molecules that are not from a disubstituted alkyne chemotype. Expert opinion: It is a critical moment for mGlu5 NAM research as recent reports from clinical trials have included some significant disappointments that have blunted prior optimism. Still, research in this area remains active, and recent years have added several more attractive small molecules to this field. There is now an arsenal of diverse chemotypes available to continue to probe this target in the hopes that a drug may yet emerge.

AB - Introduction: The pursuit of small molecule mGlu5 NAMs as treatments for a variety of psychiatric and neurodegenerative disorders has developed into a mature field. In addition to extensive preclinical studies, multiple compounds have advanced into clinical trials with the most advanced studies occurring in patients with FXS, PD-LID, and MDD. Areas covered: This review begins with an update of the clinical activity with mGlu5 NAMs, and then moves into a summary of patent applications filed since 2013. The summaries are organized into three separate sections: (1) inventions centered on improvements to existing clinical compounds; (2) new small molecules that maintain the prototypical disubstituted alkyne chemotype found in many mGlu5 NAM compounds; and (3) new small molecules that are not from a disubstituted alkyne chemotype. Expert opinion: It is a critical moment for mGlu5 NAM research as recent reports from clinical trials have included some significant disappointments that have blunted prior optimism. Still, research in this area remains active, and recent years have added several more attractive small molecules to this field. There is now an arsenal of diverse chemotypes available to continue to probe this target in the hopes that a drug may yet emerge.

KW - Basimglurant

KW - Parkinson’s disease

KW - anxiety

KW - depression

KW - dipraglurant

KW - fragile X syndrome

KW - levodopa-induced dyskinesia

KW - mavoglurant

KW - metabotropic glutamate receptor subtype 5

KW - negative allosteric modulator

UR - http://www.scopus.com/inward/record.url?scp=85016929630&partnerID=8YFLogxK

U2 - 10.1080/13543776.2017.1280466

DO - 10.1080/13543776.2017.1280466

M3 - Review article

VL - 27

SP - 691

EP - 706

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 6

ER -